New carbon dioxide-independent basal growth medium for culture of diverse tumor and nontumor cells of human and nonhuman origin.
A eukaryotic growth medium (Program Development Research Group Basal Growth Medium) was developed for CO2-independent maintenance and propagation of human and nonhuman tumor cell lines representing diverse histologies (e.g., cancers of the brain, colon, lung, ovary, and kidney, as well as leukemia and melanoma). It was also shown to be suitable for the maintenance and propagation of nontumor cells of human and nonhuman derivation. The medium derives its buffering capacity primarily from beta-glycerophosphate, exhibits a stable physiologic pH of 7.3-7.4, and is optimized to facilitate growth in atmospheric CO2. It is also useful in cellular growth and cytotoxicity assays based on either the metabolic reduction of tetrazolium reagents or protein staining. The 50% inhibitory concentration values obtained with carmustine, doxorubicin, and tamoxifen in cell lines maintained in the new medium under atmospheric CO2 were closely comparable to those obtained with these drugs against cells maintained in RPMI-1640 under a 5% CO2 environment.
Vistica
D T
DT
Division of Cancer Treatment, National Cancer Institute, Frederick Cancer Research Facility, MD 21701-1013.
Scudiero
D
D
Skehan
P
P
Monks
A
A
Boyd
M R
MR
D000818:Animals; D002021:Buffers; D002245:Carbon Dioxide / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003470:Culture Media; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007938:Leukemia / Q000473:pathology; D051379:Mice; D014407:Tumor Cells, Cultured
D002021:Buffers; D003470:Culture Media; D002245:Carbon Dioxide